China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
BOSTON, Feb. 28, 2017 -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic diseases including type 2 diabetes and obesity, announced today that Thomas Hughes, Ph.D., President and Chief Executive Officer of Zafgen, will present at two upcoming investor conferences:
- The Cowen and Company 37th Annual Health Care Conference in Boston, MA on Tuesday, March 7, 2017 at 10:00 a.m. ET; and
- The 29th Annual Roth Conference in Dana Point, CA on Tuesday, March 14, 2017 at 12:00 p.m. PT.
A live audio webcast and replay of both presentations will be available through the Events and Presentations page of the Investors section of the Company's website (www.zafgen.com) for 90 days following the conclusion of the live event.
About Zafgen
Zafgen (Nasdaq:ZFGN) is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by metabolic diseases including type 2 diabetes and obesity. Zafgen is focused on developing novel therapeutics that treat the underlying biological mechanisms of metabolic diseases through the MetAP2 pathway. Zafgen has pioneered the study of MetAP2 inhibitors in both common and rare forms of obesity. Zafgen's lead product candidate is ZGN-1061, which is a novel, first-in-class, twice-weekly subcutaneous injection. Zafgen aspires to improve the lives of patients through targeted treatments and has assembled a team accomplished in bringing therapies to patients affected by metabolic diseases.
Investor Relations Contact: Argot Partners Investor Relations Laura Perry or Glenn Garmont 212-600-1902 [email protected] [email protected]
